You are here

All reports

Inspection report

Date of Inspection: 1 May 2013
Date of Publication: 25 May 2013
Inspection Report published 25 May 2013 PDF

The service should have quality checking systems to manage risks and assure the health, welfare and safety of people who receive care (outcome 16)

Meeting this standard

We checked that people who use this service

  • Benefit from safe quality care, treatment and support, due to effective decision making and the management of risks to their health, welfare and safety.

How this check was done

We looked at the personal care or treatment records of people who use the service, carried out a visit on 1 May 2013, talked with people who use the service and talked with carers and / or family members. We talked with staff and reviewed information given to us by the provider.

Our judgement

The provider had an effective system to regularly assess and monitor the quality of service that people receive. The provider had an effective system in place to identify, assess and manage risks to the health, safety and welfare of people who use the service and others.

Reasons for our judgement

People who use the service were asked for their views about their care and treatment and these were acted on. We saw that people could give comments on a daily basis when they attended this location as well as in a formal annual survey of all the people who have used the service. This feedback was monitored and reviewed at the Integrated Governance Committee which met monthly and reported to the Medical Advisory Committee.

The Integrated Governance Committee was the means by which the service monitored incidents, complaints and risk as well as people's satisfaction. Decisions about care and treatment were made by the appropriate staff at the appropriate level in consultation with people who were participating in the clinical trials.

Sarah Cannon Research UK was also monitored by the sponsors of the clinical trials so that the trials were conducted to the protocols that had been agreed. Drugs used in the trials were approved for use by the Medicines and Healthcare Regulatory Agency (MHRA). We saw that there was an internal quality assurance process for each clinical trial that included audits of consent and adherence to the trial protocols.

In addition Sarah Cannon was accredited by CHKS (Comparative Health Knowledge System) who reviewed the service's compliance against oncology care standards in the autumn of 2012. This combined data analysis with site assessment to benchmark care standards against national quality standards and identify areas of good practice and opportunities for improvement.